Teva Identifies Teriparatide Importance Amid US Launch Drought
Israeli Firm Sees 15% North America Gx Sales Decline In Q1
Executive Summary
Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.
You may also be interested in...
Five Things Facing Teva’s New CEO Richard Francis
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
Strides Says Forsteo Biosimilar ‘Significant Product’, Seeks New Minority Investor In Stelis
Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months
Blocked Pipeline Leads Teva’s US Generics To Fall Well Below $1bn Floor
Teva’s final quarterly earnings call of the year was indicative of its continued need to push valuable pipeline projects in the US to commercialization, as it once again lowered its full-year 2022 revenue guidance.